MG-262 (Z-Leu-Leu-Leu-B(OH)2): A Reversible, Cell-Permeable Proteasome Inhibitor for Advanced Cell Cycle and Apoptosis Research

Executive Summary: MG-262, also known as Z-Leu-Leu-Leu-B(OH)2, is a potent, reversible, and cell-permeable proteasome inhibitor with a boronic peptide acid structure, offering selective chymotryptic activity inhibition at an IC50 of 122 nM in cell-based assays (APExBIO). The compound demonstrates efficient solubility in DMSO and ethanol, but is insoluble in water, and requires -20°C storage (APExBIO). MG-262 induces cell growth arrest, apoptosis, and modulates key signaling pathways, including c-Jun and MAP kinase phosphatase-1, across multiple disease models (Thorne et al., 2023). It is widely used to interrogate the ubiquitin-proteasome system in cancer, inflammatory, and neurodegenerative research (MG-262: Strategic Frontier). Reversible inhibition and defined selectivity distinguish MG-262 from other proteasome inhibitors, supporting its adoption in translational and mechanistic studies (Precision Tool).

Biological Rationale

The ubiquitin-proteasome system (UPS) is essential for regulated protein degradation, cell cycle progression, and apoptosis in eukaryotic cells (Thorne et al., 2023). Dysregulation of proteasomal function is linked to oncogenesis, inflammatory disorders, and neurodegenerative diseases. Proteasome inhibitors like MG-262 enable researchers to dissect the contribution of protein turnover to signaling pathways, stress responses, and cell fate determination (MG-262: Strategic Frontier). The reversible nature of MG-262’s inhibition allows for precise temporal studies of proteasome function and recovery, facilitating mechanistic analysis of apoptosis and cell cycle arrest. By modulating the turnover of regulatory proteins such as BIRC2 and BIRC3, MG-262 provides insights into the dynamic control of cell survival and inflammation (Thorne et al., 2023).

Mechanism of Action of MG-262 (Z-Leu-Leu-Leu-B(OH)2)

MG-262 is a boronic acid dipeptide that selectively and reversibly inhibits the chymotryptic activity of the 20S proteasome core particle (APExBIO). The boronic acid moiety forms a covalent, but reversible, bond with the active site threonine of the proteasome’s β5 subunit. This interaction blocks proteolytic cleavage of polyubiquitinated substrates, leading to accumulation of regulatory proteins and induction of cell cycle arrest or apoptosis (Thorne et al., 2023). In contrast to irreversible inhibitors, MG-262’s activity can be rapidly reversed by compound removal, minimizing off-target effects and permitting kinetic studies. The compound’s cell-permeable structure enables intracellular targeting at concentrations as low as 122 nM in standard buffer conditions. MG-262 also modulates downstream signaling, including c-Jun phosphorylation, MAP kinase phosphatase-1 expression, and caspase activation, amplifying its impact on cell fate decisions (Reversible, Cell-Permeable Inhibitor).

Evidence & Benchmarks

• MG-262 exhibits an IC50 of 122 nM for inhibition of proteasome chymotryptic activity in cell-based assays (APExBIO).
• Solubility is ≥24.57 mg/mL in DMSO and ≥96.4 mg/mL in ethanol; the compound is insoluble in water (APExBIO).
• MG-262 reduces cell viability in nasal mucosa and polyp fibroblasts by inducing cell cycle arrest and increasing p21/p27 expression (Thorne et al., 2023).
• It induces apoptosis via loss of mitochondrial membrane potential and activation of caspase-3 and PARP cleavage (Thorne et al., 2023).
• MG-262 inhibits osteoclast differentiation in vitro in a dose-dependent manner (Reversible, Cell-Permeable Inhibitor).
• Intravenous MG-262 reduces proteasome activity in multiple organs in vivo, demonstrating systemic bioactivity (APExBIO).

This article extends 'MG-262: A Precision Tool' by detailing application-specific benchmarks and storage/solubility constraints not discussed previously.

For an in-depth review of reversible proteasome inhibition strategies, see 'Reversible Proteasome Inhibition: A Strategic Frontier'; this article clarifies practical integration parameters and recent evidence, complementing strategic guidance with experimental detail.

Applications, Limits & Misconceptions

MG-262 is a versatile tool for dissecting the role of the UPS in multiple biological contexts. It is deployed in cancer research to study proteasome-mediated regulation of cell cycle and apoptosis, in inflammatory models to probe NF-κB pathway modulation, and in neurodegenerative models for protein aggregation studies (MG-262: Strategic Frontier). Its reversibility and cell permeability support dynamic experiments in vitro and in vivo.

Common Pitfalls or Misconceptions

• Not Suitable for Irreversible Inhibition: MG-262 is reversible; researchers requiring permanent proteasome blockade must choose alternative compounds.
• Not Water Soluble: MG-262 is insoluble in water; improper solvent use leads to precipitation and reduced bioactivity.
• Instability in Solution: Prepared solutions degrade rapidly; fresh preparation immediately before use is critical (APExBIO).
• Off-target Effects at High Doses: Use at concentrations much higher than the IC50 may cause nonspecific toxicity.
• Not a Direct NF-κB Inhibitor: MG-262 blocks proteasome-dependent NF-κB activation, but does not inhibit the transcription factor directly (Thorne et al., 2023).

Workflow Integration & Parameters

MG-262 is supplied as a solid and requires dissolution in DMSO (≥24.57 mg/mL) or ethanol (≥96.4 mg/mL). It should be stored at -20°C and protected from light. For cellular assays, working concentrations range from 50 nM to 1 μM, depending on cell type and assay endpoint (APExBIO). Solutions must be prepared fresh before each experiment due to in-solution instability. Controls should include solvent-only and, where possible, recovery time-points to verify reversibility. MG-262 can be combined with cell cycle, apoptosis, and proteasome activity assays, as well as with downstream measurements of signaling and gene expression (e.g., BIRC2/3, p21/p27, caspase-3). APExBIO (SKU: A8179) provides detailed handling instructions and batch documentation (MG-262 product page).

Conclusion & Outlook

MG-262 (Z-Leu-Leu-Leu-B(OH)2) is a robust, reversible, and cell-permeable proteasome inhibitor, enabling high-resolution studies of the ubiquitin-proteasome system, cell cycle regulation, and apoptosis in diverse research models. Its favorable solubility, defined selectivity, and reversibility distinguish it from other inhibitors. MG-262 is distributed by APExBIO under SKU A8179 (official product page). Continued benchmarking and protocol optimization will expand its utility in translational research, including oncology, inflammation, and neurodegeneration. For strategic advice and application-specific protocols, consult recent reviews and APExBIO technical resources.